Free Allergy and Immunology CME

Find out what over 50,000 of your colleagues already know. Earn credits faster and easier with Healio CME.

Physicians specializing in Allergy or Dermatology.

Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy emphasizes the use of IVIg in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy.

The presentation consists of a single lecture, Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy, with discussion by Roy L. Freeman, MD, Richard J. Barohn, MD and Kenneth C. Gorson, MD.

After viewing Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy, you will be better able to :
• Conduct a thorough and timely evaluation and differential diagnosis of patients with chronic inflammatory demyelinating polyneuropathy.
• Devise appropriate treatment regimen for the effective management of chronic inflammatory polyneuropathy based on guidelines and clinical evidence.

Target Audiences:
This program is intended for US-based neurologists, immunologists, physician assistants, nurse practitioners, and nurses who manage, or have an interest in managing patients with immune-mediated neuropathies.

Activity Description / Statement of Need:

Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may be associated with permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Globally, it affects 0.1-1% of people, it is a common comorbidity of patients with psoriasis, affecting up to a quarter of those with moderate-to-severe disease. affecting them in a quarter percent of the U.S. population. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible. In all, patients with PsA incur about four times the direct medical costs as compared to the average medical patient.

This accredited educational activity identifies the critical components of the management process and offer solutions to close gaps in diagnosis and care, with the ultimate goals being the improvement of psoriatic arthritis management, treatment adherence, and health and cost outcomes. 

Target Audience:

The following HCPs: rheumatologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in rheumatology and immunology; and any other HCPs with an interest in or who clinically encounter patients with PsA.

Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by clinical features of esophageal dysfunction and eosinophil inflammation. EoE is mediated by type 2 helper T cell activity and precipitated primarily by dietary antigens. It may affect people of all ages and races, but the prevalence is highest amongst middle-aged Caucasian males. Approximately 30 out of every 100,000 adults in the U.S. are thought to have the condition.

By the end of the session the participant will be able to:

• Describe the patholophysiology of EoE in adults and adolescents such that it informs treatment mechanisms
• Describe the clinical presentation, complications associated with, and diagnosis EoE in adults and adolescents.
• Identify current drug treatment options and dietary strategies available for the management of EoE, including strengths and weaknesses of each, and apply them to patient cases using evidence-based medicine.
• Identify issues with current practices for EoE and strategies to address them.

Target Audience:

The following healthcare professionals: allergists, immunologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who specialize in the aforementioned fields; and any other healthcare professionals with an interest in or who may clinically encounter patients with EoE.